What is it about?
Antiphospholipid antibodies (aPL) promote endothelial dysfunction, inflammation and procoagulant state. We investigated the effect of hydroxychloroquine (HCQ) on prothrombotic state and endothelial function in mice and in human aortic endothelial cells (HAEC).
Featured Image
Why is it important?
This study provides new evidence that HCQ improves procoagulant status and vascular function in APS by modulating eNOS, leading to an improvement in the production of NO.
Perspectives
Therefore, HCQ may be of special relevance in clinical practice and, this hypothesis warrants evaluation. In this regard, we are currently conducting a ran- domized controlled trial (APLAQUINE) that investigates whether treatment with HCQ modu- lates vascular endothelial function and coagulation parameters in patients with APS (NCT02595346).
Paul Billoir
Rouen University Hospital Vascular Hemostasis Unit
Read the Original
This page is a summary of: Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction, PLOS One, March 2019, PLOS,
DOI: 10.1371/journal.pone.0212614.
You can read the full text:
Contributors
The following have contributed to this page
